Preventive Cardiology — MCQs

10 questions

According to WHO Global Action Plan for prevention and control of Non-communicable Diseases 2013-2020, targeted reduction in prevalence of raised blood pressure is :

Which of the following is NOT considered a risk factor for atherosclerosis?

What is WHO's global target for the prevention and control of non-communicable diseases by 2025 regarding hypertension reduction?

For a patient diagnosed with dyslipidemia characterized by elevated LDL cholesterol levels, what is the most appropriate treatment?

True about Cardiovascular disease (CVD)

Primordial prevention in myocardial infarction is all except -

Atorvastatin is used as an anti-dyslipidemic drug. These drugs inhibit their target enzyme by:-

According to WHO guidelines, to decrease both coronary heart disease and diabetes, triple treatment involves:

In which of the following clinical conditions does the use of anticoagulants provide maximum benefit?

Q10

An adolescent with type 1 diabetes returns for a follow-up visit after his annual check-up last week. You note that his serum glucose is elevated, and his glycosylated hemoglobin (hemoglobin A1C) is 16.7%. This finding suggests poor control of his diabetes over at least which of the following time-periods?

Preventive Cardiology Indian Medical PG Practice Questions and MCQs

Question 1: According to WHO Global Action Plan for prevention and control of Non-communicable Diseases 2013-2020, targeted reduction in prevalence of raised blood pressure is :

A. 25% (Correct Answer)
B. 33%
C. 10%
D. 50%

Explanation: ***25%*** - The **WHO Global Action Plan for the Prevention and Control of Non-communicable Diseases 2013-2020** set a target to reduce the prevalence of **raised blood pressure** (hypertension) by 25%. - This target is one of the nine global NCD targets aimed at curbing the NCD epidemic by 2025. *33%* - A 33% reduction is not a specific target for raised blood pressure in the WHO Global Action Plan for NCDs. - While significant reductions are sought across various NCD risk factors, this exact percentage isn't linked to hypertension prevalence. *10%* - A 10% reduction is generally considered too low for the ambitious goals set by the WHO for major NCD risk factors like raised blood pressure. - The plan aims for more substantial public health impact. *50%* - A 50% reduction in the prevalence of raised blood pressure is a very ambitious target, even beyond the scope of initial global NCD goals for this particular indicator. - While desirable, it was not the specific target set for raised blood pressure in the 2013-2020 action plan.

Question 2: Which of the following is NOT considered a risk factor for atherosclerosis?

A. Smoking
B. Low LDL cholesterol (Correct Answer)
C. Hypercholesterolemia
D. Hypertension

Explanation: ***Low LDL cholesterol*** - **Low levels of low-density lipoprotein (LDL) cholesterol** are protective against atherosclerosis [3]. - LDL cholesterol is often referred to as "bad" cholesterol because high levels contribute to the **buildup of fatty plaques in arteries**. *Smoking* - **Smoking** is a major independent risk factor for atherosclerosis, damaging the **endothelium** and promoting plaque formation. - It increases **oxidative stress** and reduces **nitric oxide bioavailability**, leading to vasoconstriction and inflammation [2]. *Hypercholesterolemia* - **Hypercholesterolemia**, particularly high levels of **LDL cholesterol**, is a primary risk factor as it contributes to the deposition of cholesterol in arterial walls [3]. - This leads to the formation of **atheromatous plaques** which narrow arteries and impede blood flow [1]. *Hypertension* - **Hypertension (high blood pressure)** damages the arterial walls, making them more susceptible to the accumulation of plaque [1]. - The constant high pressure creates **shear stress**, compromising the integrity of the **endothelial lining**.

Question 3: What is WHO's global target for the prevention and control of non-communicable diseases by 2025 regarding hypertension reduction?

A. 25% (Correct Answer)
B. 35%
C. 55%
D. 75%

Explanation: ***25%*** - The World Health Organization (WHO) set a global target to achieve a **25% relative reduction in the prevalence of raised blood pressure** (hypertension) by 2025. - This target is part of the WHO's **Global Action Plan for the Prevention and Control of Non-Communicable Diseases (2013-2025)**, one of nine voluntary global targets aiming to reduce premature mortality from NCDs. - The target allows for flexibility: countries can either achieve the 25% relative reduction or contain the prevalence according to national circumstances. *35%* - A 35% reduction in hypertension prevalence is **not a specific global target** set by the WHO for 2025. - The WHO established standardized targets (including 25% for hypertension) to enable consistent monitoring and comparison across countries. *55%* - A 55% reduction is **significantly higher** than the internationally agreed-upon global target for hypertension reduction by 2025. - Such an aggressive target would be challenging to achieve systematically across diverse healthcare systems worldwide within this timeframe. *75%* - A 75% reduction in hypertension prevalence represents an **unrealistically high goal** for the WHO's 2025 targets. - Global health targets are designed to be ambitious yet attainable, balancing aspiration with feasibility to encourage widespread implementation and measurable progress.

Question 4: For a patient diagnosed with dyslipidemia characterized by elevated LDL cholesterol levels, what is the most appropriate treatment?

A. Fibric acid derivatives
B. Nicotinic acid
C. Bile acid-binding resins
D. Statins (Correct Answer)

Explanation: ***Statins*** - **Statins** are the frontline treatment for elevated **LDL cholesterol**, significantly reducing **cardiovascular risk** by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. - They effectively **lower LDL levels** and have additional **pleiotropic effects** such as anti-inflammatory properties and plaque stabilization. *Fibric acid derivatives* - **Fibric acid derivatives** are primarily used to treat **hypertriglyceridemia** and can moderately increase HDL cholesterol, but they are less effective at lowering LDL cholesterol compared to statins. - They act by activating **PPAR-alpha**, leading to increased fatty acid oxidation and reduced triglyceride synthesis. *Nicotinic acid* - **Nicotinic acid** (niacin) is effective in **lowering triglycerides** and raising **HDL cholesterol**, but its impact on LDL cholesterol is less pronounced than statins, and it is associated with significant side effects like flushing. - It works by inhibiting hepatic VLDL synthesis and secretion, which indirectly impacts LDL formation. *Bile acid-binding resins* - **Bile acid-binding resins** reduce LDL cholesterol by binding bile acids in the intestine, leading to increased hepatic synthesis of bile acids from cholesterol and upregulation of LDL receptors. - While effective, they are generally less potent than statins and often cause **gastrointestinal side effects** such as constipation and bloating.

Question 5: True about Cardiovascular disease (CVD)

A. Coronary heart disease causes 25% of total deaths
B. Urban and rural areas have equal incidence
C. Primordial prevention is best strategy (Correct Answer)
D. RHD is the most common cause of CVD

Explanation: ***Primordial prevention is best strategy*** - **Primordial prevention** aims to prevent the development of risk factors for CVD in the first place, often starting in childhood. - This strategy targets entire populations with public health initiatives to promote healthy lifestyles and environments, making it the most effective long-term approach to reduce CVD burden. *Coronary heart disease causes 25% of total deaths* - **Coronary heart disease (CHD)** accounts for approximately 16-17% of all deaths globally, not 25%. - While CHD is a leading cause of death, stating it causes 25% of total deaths is an overestimation. *RHD is the most common cause of CVD* - **Rheumatic Heart Disease (RHD)** is an important cause of cardiovascular disease in developing countries including India. - However, **ischemic heart disease** (coronary artery disease) and **hypertension** are the most common causes of CVD globally and in India, not RHD. *Urban and rural areas have equal incidence* - The incidence of cardiovascular disease differs significantly between **urban and rural areas**. - Urban areas typically have higher CVD incidence due to lifestyle factors (sedentary behavior, unhealthy diet, stress), though rural rates are increasing due to epidemiological transition.

Question 6: Primordial prevention in myocardial infarction is all except -

A. Change in life style
B. Change in Nutritional habits
C. Maintenance of normal body weight
D. Screening for hypertension (Correct Answer)

Explanation: ***Screening for hypertension*** - **Screening for hypertension** falls under **primary prevention**, as it aims to detect and treat a risk factor in individuals who have already developed a predisposition to the disease. - **Primordial prevention** focuses on preventing the development of risk factors themselves, rather than detecting them once they've emerged. *Change in life style* - **Lifestyle changes** such as promoting regular physical activity and avoiding smoking are key components of **primordial prevention**, preventing the development of risk factors like obesity and hypertension. - These interventions aim to stop risk factors from even appearing in healthy populations. *Change in Nutritional habits* - Promoting **healthy nutritional habits** from an early age is a fundamental strategy in **primordial prevention**, aiming to prevent the development of conditions like obesity and hyperlipidemia. - This proactive approach seeks to establish healthy patterns before disease risk factors take hold. *Maintenance of normal body weight* - Encouraging and supporting the **maintenance of normal body weight** in the general population is a classic example of **primordial prevention**. - This prevents the emergence of obesity, a major risk factor for cardiovascular diseases like myocardial infarction.

Question 7: Atorvastatin is used as an anti-dyslipidemic drug. These drugs inhibit their target enzyme by:-

A. Noncompetitive inhibition
B. Competitive inhibition (Correct Answer)
C. Irreversible inhibition
D. Uncompetitive inhibition

Explanation: ***Competitive inhibition*** - Atorvastatin is a **statin**, which acts as a **competitive inhibitor** of **HMG-CoA reductase**, the rate-limiting enzyme in cholesterol synthesis. - It competes with the natural substrate, HMG-CoA, for binding to the **active site of the enzyme**, thereby reducing cholesterol production. *Uncompetitive* - **Uncompetitive inhibitors** bind only to the **enzyme-substrate complex**, not to the free enzyme. - This type of inhibition is characterized by a decrease in both **apparent Vmax** and **apparent Km**. *Noncompetitive inhibition* - **Noncompetitive inhibitors** bind to an allosteric site on the enzyme, distinct from the active site, and can bind to either the **free enzyme or the enzyme-substrate complex**. - This leads to a decrease in the **apparent Vmax** but does not affect Km. *Irreversible inhibition* - **Irreversible inhibitors** form a **strong covalent bond** with the enzyme, permanently inactivating it. - Statins do not form covalent bonds with HMG-CoA reductase; their inhibition is **reversible** upon drug discontinuation.

Question 8: According to WHO guidelines, to decrease both coronary heart disease and diabetes, triple treatment involves:

A. Healthy diet, regular physical exercise, avoiding tobacco (Correct Answer)
B. Lipid lowering drug, avoiding tobacco, poly pill
C. Healthy diet, regular physical exercise, decreased salt intake
D. Decreased salt intake, poly pill, vegetarian diet

Explanation: ***Correct: Healthy diet, regular physical exercise, avoiding tobacco*** - This represents the **WHO's core triple intervention strategy** for primary prevention of both **coronary heart disease** and **diabetes mellitus** - **Healthy diet** addresses obesity, dyslipidemia, and insulin resistance—common risk factors for both conditions - **Regular physical exercise** improves glucose metabolism, insulin sensitivity, and cardiovascular fitness while reducing multiple CVD risk factors - **Avoiding tobacco** prevents endothelial dysfunction, reduces inflammation, and decreases risk of both macrovascular complications in diabetes and atherosclerotic heart disease - These three lifestyle modifications form the foundation of WHO's **Global Action Plan for Prevention and Control of NCDs** *Incorrect: Healthy diet, regular physical exercise, decreased salt intake* - While **decreased salt intake** is important for blood pressure control and CVD prevention, it is not part of the specific "triple treatment" framework for both CHD and diabetes - Salt reduction is more targeted toward hypertension management rather than diabetes prevention - The WHO emphasizes **tobacco avoidance** over salt reduction when addressing both conditions simultaneously *Incorrect: Lipid lowering drug, avoiding tobacco, poly pill* - These are **pharmacological interventions** rather than lifestyle modifications - The question asks about primary prevention measures that apply universally, not secondary prevention or high-risk treatment strategies - While **poly pills** have a role in secondary prevention, they are not first-line "triple treatment" for primary prevention *Incorrect: Decreased salt intake, poly pill, vegetarian diet* - **Vegetarian diet** is a specific dietary pattern, not the universal "healthy diet" recommendation - **Poly pill** is a pharmacological intervention, not suitable for population-wide primary prevention - This combination does not reflect WHO's core triple intervention framework

Question 9: In which of the following clinical conditions does the use of anticoagulants provide maximum benefit?

A. Prevention of recurrences of myocardial infarction
B. Prevention of venous thrombosis and pulmonary embolism (Correct Answer)
C. Prevention of cerebrovascular accident (stroke)
D. Retinal artery thrombosis

Explanation: ***Prevention of venous thrombosis and pulmonary embolism*** - Anticoagulants are highly effective in inhibiting the formation and extension of **venous thrombi**, thereby directly preventing **deep vein thrombosis (DVT)** and **pulmonary embolism (PE)**. - The mechanism of action targets the **coagulation cascade**, directly reducing the risk of these venous thromboembolic events, which are a major indication for anticoagulant therapy. *Prevention of recurrences of myocardial infarction* - While anticoagulants may play a secondary role, **antiplatelet agents** (e.g., aspirin, clopidogrel) are the primary therapy for preventing recurrent myocardial infarction, as **arterial thrombi** are predominantly platelet-rich. - Anticoagulants are used in specific high-risk situations post-MI (e.g., **atrial fibrillation**, left ventricular thrombus) but are not generally considered the primary preventive strategy. *Cerebrovascular accident* - The benefit of anticoagulants for stroke prevention is primarily significant in cases of **cardioembolic stroke** (e.g., due to **atrial fibrillation**) where they prevent clot formation in the heart. - For non-cardioembolic **ischemic strokes** (e.g., thrombotic or lacunar), antiplatelet agents are generally preferred for secondary prevention. *Retinal artery thrombosis* - **Retinal artery thrombosis** is often caused by **arterial atherosclerosis** and **embolism** from the carotid arteries or heart, where antiplatelet agents are typically primary. - The role of anticoagulants here is limited to specific causes like **atrial fibrillation** or in patients already on anticoagulation for other indications.

Question 10: An adolescent with type 1 diabetes returns for a follow-up visit after his annual check-up last week. You note that his serum glucose is elevated, and his glycosylated hemoglobin (hemoglobin A1C) is 16.7%. This finding suggests poor control of his diabetes over at least which of the following time-periods?

A. 1 month
B. 2 months (Correct Answer)
C. 8 hours
D. 1 week

Explanation: ***2 months*** - **Hemoglobin A1c** reflects the average blood glucose levels over the preceding **2-3 months**, as it measures glycated hemoglobin within red blood cells. - Red blood cells have a lifespan of approximately 120 days, so this test provides a good indication of long-term glycemic control. [2] *1 month* - While recent glucose levels contribute to A1c, a 1-month period is generally too short to reflect the full averaging effect of the test. - A 1-month period would not fully capture the complete lifespan of red blood cells, which is central to A1c's utility as a long-term marker. *8 hours* - An 8-hour period is far too short to be reflected by hemoglobin A1c, which assesses average glucose over weeks to months. - This timeframe is more relevant for **fasting glucose** or immediate postprandial glucose levels, not long-term control. [1] *1 week* - Similar to a 1-month period, 1 week is insufficient to reflect the long-term glucose control captured by **hemoglobin A1c**. - **Fructosamine** levels are a better indicator for glucose control over a 1-2 week period, as it reflects glycated proteins with a shorter half-life.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free